StockData
Ocular Therapeutix, Inc logo

Ocular Therapeutix, Inc (OCUL) stock

OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)

Close on Nov 17, 2026Market cap $1.32BP/E –Yield –

Ocular Therapeutix cash

Cash and short-term investments held at the end of each period.

Ocular Therapeutix's cash was $598.64M at Jun 30, 2026. For fiscal 2025 it was $737.06M, up 87.2% from the year before. Over ten years it grew 21.5% a year on average. The highest annual figure on record is $737.06M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$737.06M+87.2%
FY2024Dec 31, 2024$393.72M+101.1%
FY2023Dec 31, 2023$195.81M+88.2%
FY2022Dec 31, 2022$104.06M-37.3%
FY2021Dec 31, 2021$165.93M-27.8%
FY2020Dec 31, 2020$229.82M+308.9%
FY2019Dec 31, 2019$56.20M-7.4%
FY2018Dec 31, 2018$60.68M+46.1%
FY2017Dec 31, 2017$41.54M-40.6%
FY2016Dec 31, 2016$69.87M-33.6%
FY2015Dec 31, 2015$105.29M+40.7%
FY2014Dec 31, 2014$74.83M+327.5%
FY2013Dec 31, 2013$17.51M-26.6%
FY2012Dec 31, 2012$23.85M+347.5%
FY2011Dec 31, 2011$5.33M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$598.64M+53.1%
Q1 FY2026Mar 31, 2026$666.70M+90.7%
Q4 FY2025Dec 31, 2025$737.06M+87.2%
Q3 FY2025Sep 30, 2025$344.77M-19.3%
Q2 FY2025Jun 30, 2025$391.13M-14.9%
Q1 FY2025Mar 31, 2025$349.68M-27.6%
Q4 FY2024Dec 31, 2024$393.72M+101.1%
Q3 FY2024Sep 30, 2024$427.22M+286.4%
Q2 FY2024Jun 30, 2024$459.69M+590.2%
Q1 FY2024Mar 31, 2024$482.89M+511.0%
Q4 FY2023Dec 31, 2023$195.81M+88.2%
Q3 FY2023Sep 30, 2023$110.55M-8.6%
Q2 FY2023Jun 30, 2023$66.61M-50.5%
Q1 FY2023Mar 31, 2023$79.03M-45.7%
Q4 FY2022Dec 31, 2022$104.06M-37.3%
Q3 FY2022Sep 30, 2022$120.95M-32.5%
Q2 FY2022Jun 30, 2022$134.54M-29.9%
Q1 FY2022Mar 31, 2022$145.42M-30.5%
Q4 FY2021Dec 31, 2021$165.93M-27.8%
Q3 FY2021Sep 30, 2021$179.28M+153.8%
Q2 FY2021Jun 30, 2021$191.86M+127.6%
Q1 FY2021Mar 31, 2021$209.38M+334.8%
Q4 FY2020Dec 31, 2020$229.82M+308.9%
Q3 FY2020Sep 30, 2020$70.64M+8.0%
Q2 FY2020Jun 30, 2020$84.29M+36.5%
Q1 FY2020Mar 31, 2020$48.15M-36.9%
Q4 FY2019Dec 31, 2019$56.20M-7.4%
Q3 FY2019Sep 30, 2019$65.41M+15.0%
Q2 FY2019Jun 30, 2019$61.77M+8.7%
Q1 FY2019Mar 31, 2019$76.25M+21.2%
Q4 FY2018Dec 31, 2018$60.68M+46.1%
Q3 FY2018Sep 30, 2018$56.86M+11.1%
Q2 FY2018Jun 30, 2018$56.83M-14.0%
Q1 FY2018Mar 31, 2018$62.91M-21.7%
Q4 FY2017Dec 31, 2017$41.54M-40.6%
Q3 FY2017Sep 30, 2017$51.17M-32.5%
Q2 FY2017Jun 30, 2017$66.05M–
Q1 FY2017Mar 31, 2017$80.38M–
Q4 FY2016Dec 31, 2016$69.87M–
Q3 FY2016Sep 30, 2016$75.75M–

More Ocular Therapeutix figures

See a number that looks wrong?